BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9570520)

  • 1. Avoidance of self-reactivity results in skewed CTL responses to rare components of synthetic immunogens.
    Purcell AW; Chen W; Ede NJ; Gorman JJ; Fecondo JV; Jackson DC; Zhao Y; McCluskey J
    J Immunol; 1998 Feb; 160(3):1085-90. PubMed ID: 9570520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to polyoma virus-induced tumors correlates with CTL recognition of an immunodominant H-2Dk-restricted epitope in the middle T protein.
    Lukacher AE; Wilson CS
    J Immunol; 1998 Feb; 160(4):1724-34. PubMed ID: 9469430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design.
    Chen W; Ede NJ; Jackson DC; McCluskey J; Purcell AW
    J Immunol; 1996 Aug; 157(3):1000-5. PubMed ID: 8757603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
    Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
    J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope.
    Baratin M; Kayibanda M; Ziol M; Romieu R; Briand JP; Guiller JG; Viguier M
    J Pept Sci; 2002 Jul; 8(7):327-34. PubMed ID: 12148782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
    Kittlesen DJ; Thompson LW; Gulden PH; Skipper JC; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH; Slingluff CL
    J Immunol; 1998 Mar; 160(5):2099-106. PubMed ID: 9498746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides.
    Wang W; Man S; Gulden PH; Hunt DF; Engelhard VH
    J Immunol; 1998 Feb; 160(3):1091-7. PubMed ID: 9570521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery.
    Sandberg JK; Grufman P; Wolpert EZ; Franksson L; Chambers BJ; Kärre K
    J Immunol; 1998 Apr; 160(7):3163-9. PubMed ID: 9531271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactive and syngeneic CTL are comparably dependent on interaction with MHC class I alpha-helical residues.
    Hornell TM; Solheim JC; Myers NB; Gillanders WE; Balendiran GK; Hansen TH; Connolly JM
    J Immunol; 1999 Sep; 163(6):3217-25. PubMed ID: 10477590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural complexity of antigenic determinants for class I MHC-restricted, hapten-specific T cells. Two qualitatively differing types of H-2Kb-restricted TNP epitopes.
    Martin S; von Bonin A; Fessler C; Pflugfelder U; Weltzien HU
    J Immunol; 1993 Jul; 151(2):678-87. PubMed ID: 8335903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
    Zeh HJ; Perry-Lalley D; Dudley ME; Rosenberg SA; Yang JC
    J Immunol; 1999 Jan; 162(2):989-94. PubMed ID: 9916724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential binding of a minor histocompatibility antigen peptide to H-2 class I molecules correlates with immune responsiveness.
    Wettstein PJ; van Bleek GM; Nathenson SG
    J Immunol; 1993 Apr; 150(7):2753-60. PubMed ID: 7681080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
    Ma H; Kapp JA
    Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
    Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
    J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes.
    Suzuki K; Sahara H; Okada Y; Yasoshima T; Hirohashi Y; Nabeta Y; Hirai I; Torigoe T; Takahashi S; Matsuura A; Takahashi N; Sasaki A; Suzuki M; Hamuro J; Ikeda H; Wada Y; Hirata K; Kikuchi K; Sato N
    J Immunol; 1999 Sep; 163(5):2783-91. PubMed ID: 10453022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H2-M3 presents a nonformylated viral epitope to CTLs generated in vitro.
    Byers DE; Fischer Lindahl K
    J Immunol; 1998 Jul; 161(1):90-6. PubMed ID: 9647211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominance of a single peptide bound to the class I(B) molecule, Qa-1b.
    DeCloux A; Woods AS; Cotter RJ; Soloski MJ; Forman J
    J Immunol; 1997 Mar; 158(5):2183-91. PubMed ID: 9036964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in TCR-MHC contacts subsequent to cross-recognition of class I MHC and singly substituted peptide variants.
    Ono T; DiLorenzo TP; Wang F; Kalergis AM; Nathenson SG
    J Immunol; 1998 Nov; 161(10):5454-63. PubMed ID: 9820521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.